Table 5. Median eGFR during long-term follow-up.

	Induction therapy			p-value
	No	ATG	Alemtuzumab
Before Tx	94.14 (5.4–534.9)	96.1 (43.9–223.9)	100 (23.2–552)	*0.084,**0.327
3 months	61 (13.24–221)	63.74 (25.5–133.8)	71.4 (18.2–365)	*0.003, **0.413
6 months	51.13 (10.6–128.6)	50.5 (21.8–114.6)	58.6 (17.8–244.6)	*0.006, **0.167
1 year	45.1 (7.97–114.38)	46.9 (18.1–125)	56.2 (15.8–167.7)	*<0.001,**<0.05
2 years	46.6 (9.6–126.2)	45.3 (16.9–94.6)	56.4 (15.5–156.3)	*0.011, **<0.05
3 years	46.2 (5.93–110.19)	43.4 (14.1–85)	57 (21.8–221)	*0.015, **<0.05
≥ 4 years	47.25 (5.7–123.1)	46.03 (8.7–86.6)	50.9 (12.7–142.8)	*0.635, **0.304

* NI vs Alemtuzumab;

** ATG vs Alemtuzumab